Psych MEQs / SAQs · General adult psychiatry — bipolar and related disorders
Severe manic crisis: work-up, RT/seclusion, antimanic algorithm (MEQ)
FRANZCP-style MEQ on acute psychotic mania: medical clearance, RT/seclusion least-restrictive ladder, lithium/SGA algorithm with doses, antidepressant cessation, and maintenance planning.
On this page
Study tools
Target exams
Model answer
Reveal model answerShowHide
(i) Episode and risk. Operational diagnosis: bipolar I disorder, current episode manic, severe, with psychotic features (grandiose delusions; duration 8 days; marked impairment; hospitalisation indicated). Risk domains: violence to staff/public, property damage, financial catastrophe, sexual disinhibition, absconding, vulnerability, driving, possible suicide if mixed features evolve, forensic sequelae. Capacity for treatment likely impaired; consider least-restrictive involuntary pathway under local law.[3]
(ii) Medical work-up. Even with known bipolar illness: observations already partly reassuring (afebrile, normal glucose/SpO2) but complete FBC, U&E/eGFR, calcium, LFT, TFT, ECG, pregnancy test if relevant, UDS. Review for withdrawal, occult infection, or other medical contributors to agitation. Escalate neuroimaging/EEG/autoimmune work-up if atypical features appear. Baselines are mandatory before re-starting lithium/SGA.[7][3]
(iii) Behavioural emergency. De-escalate: one spokesperson, low stimulation, clear simple choices, offer oral medication first.[2] If parenteral RT needed after failed oral offer: examples within protocol — lorazepam 1–2 mg IM, or promethazine 25–50 mg IM, or haloperidol 5 mg IM with anticholinergic availability, or olanzapine 5–10 mg IM — never IM olanzapine plus parenteral benzodiazepine. Post-RT: continuous observation of airway, RR, SpO2, BP, conscious level. Seclusion only if still unsafe: time-limited, continuous observation, documented authorisation, avoid prolonged prone restraint, regular reviews, debrief, and ensure antimanic cover is started so seclusion is not the treatment.[2]
(iv) Pharmacotherapy. Stop sertraline (polarity-unsafe; may have contributed to switch/escalation).[5][3] After baselines: re-start lithium (e.g. 450–900 mg/day titrated) aiming for 12-hour trough about 0.8–1.2 mmol/L in acute mania; level at 5–7 days; educate on toxicity (coarse tremor, ataxia, vomiting, confusion) and interactions.[4][3] Add SGA for severe psychotic mania — e.g. olanzapine 10–20 mg/day oral (or other evidence-based SGA). Combination is appropriate for severe illness.[1][3] Short-term benzodiazepine for sleep/arousal. Consider valproate only if lithium unsuitable and pregnancy risk managed; loading ~20–30 mg/kg/day is a selected-protocol option, not automatic. ECT if extreme ongoing risk or non-response. Lithium "loading" means supervised faster titration with levels — not reckless boluses without renal baselines.[4][3]
(v) Maintenance and psychosocial. Before discharge: continue effective regimen into early recovery; simplify toward lithium-first prevention when tolerated (BALANCE context); metabolic and lithium monitoring schedule; psychoeducation; sleep regularity; early-warning signs with partner; crisis contacts; substance advice; outpatient follow-up timed before discharge.[6][3]
References7ShowHide
- [1]Cipriani A, Barbui C, Salanti G, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis Lancet, 2011.PMID 21851976
- [2]Patel MX, Sethi FN, Barnes TR, et al. Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation J Psychopharmacol, 2018.PMID 29882463
- [3]Malhi GS, Bell E, Bassett D, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders Aust N Z J Psychiatry, 2021.PMID 33353391
- [4]McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis Lancet, 2012.PMID 22265699
- [5]Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression N Engl J Med, 2007.PMID 17392295
- [6]Geddes JR, Goodwin GM, Rendell J, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial Lancet, 2010.PMID 20092882
- [7]Nordstrom K, Zun LS, Wilson MP, et al. Medical evaluation and triage of the agitated patient: consensus statement of the American Association for Emergency Psychiatry Project BETA medical evaluation workgroup West J Emerg Med, 2012.PMID 22461915